Go Pro
→ Is the fix for AI's runaway power problem your golden ticket? (From Eagle Publishing) (Ad)tc pixel Free IRD Stock Alerts

Opus Genetics (IRD) Financials

Opus Genetics logo
$4.02 -0.08 (-1.95%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$3.95 -0.07 (-1.82%)
As of 07/9/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Opus Genetics

Annual Income Statements for Opus Genetics

This table shows Opus Genetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -14 -9.31 -25 -14 -6.17 -25 -57 18 -9.99 -58 -50
Consolidated Net Income / (Loss)		 -14 -9.31 -25 -14 -6.17 -25 -57 18 -9.99 -58 -50
Net Income / (Loss) Continuing Operations		 -14 -9.31 -25 -14 -6.17 -25 -57 18 -9.99 -58 -50
Total Pre-Tax Income 		-14 -9.31 -25 -14 -6.17 -25 -57 18 -9.97 -58 -50
Total Operating Income		 -18 -16 -17 -21 -4.19 -20 -23 18 -11 -62 -39
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.59 40 19 11 14
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.59 40 19 11 14
Operating Revenue		 0.00 0.00 0.00 0.00 - 0.00 0.59 40 19 11 14
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 18 16 17 21 4.19 20 23 22 30 73 53
Selling, General & Admin Expense		 6.12 6.32 6.64 7.43 1.82 2.82 8.12 7.27 12 18 22
Research & Development Expense		 12 10 11 13 2.37 17 15 14 18 55 31
Total Other Income / (Expense), net		 3.88 7.11 -7.94 6.17 -1.98 -4.65 -34 -0.02 0.59 4.54 -11
Interest Expense		 0.21 0.31 0.55 - 1.41 3.18 0.00 0.01 - 0.00 0.13
Other Income / (Expense), net		 3.99 7.30 -7.59 5.91 -0.57 -1.48 -34 -0.01 0.59 4.54 -11
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.32 0.01 0.00 0.00
Basic Earnings per Share		 ($0.79) ($0.43) $0.00 ($5.25) ($2.17) ($5.28) ($3.82) $0.90 ($0.46) ($2.15) ($0.80)
Weighted Average Basic Shares Outstanding		 18.24M 21.74M 27.39M 2.74M 2.84M 4.66M 14.85M 19.93M 21.59M 26.72M 62.22M
Diluted Earnings per Share		 ($0.79) ($0.43) $0.00 ($5.25) ($2.17) ($5.28) ($3.82) $0.87 ($0.46) ($2.15) ($0.80)
Weighted Average Diluted Shares Outstanding		 18.24M 21.74M 27.39M 2.74M 2.84M 4.66M 14.85M 20.60M 21.59M 26.72M 62.22M
Weighted Average Basic & Diluted Shares Outstanding		 18.24M 21.74M 27.39M 2.74M 2.84M 4.66M 18.99M 20.95M 24.81M 45.48M 71.15M

Quarterly Income Statements for Opus Genetics

This table shows Opus Genetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 5.56 -4.80 -7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -17 -66
Consolidated Net Income / (Loss)		 5.56 -4.80 -7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -17 -66
Net Income / (Loss) Continuing Operations		 5.56 -4.80 -7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -17 -66
Total Pre-Tax Income 		5.58 -4.80 -7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -17 -66
Total Operating Income		 6.39 -5.43 -7.71 -8.33 -8.01 -38 -9.93 -8.91 -8.31 -11 -14
Total Gross Profit		 12 1.69 1.71 1.11 3.87 4.30 4.37 2.88 3.08 3.87 2.16
Total Revenue		 12 1.69 1.71 1.11 3.87 4.30 4.37 2.88 3.08 3.87 2.16
Operating Revenue		 12 1.69 1.71 1.11 3.87 4.30 4.37 2.88 3.08 3.87 2.16
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 5.55 7.12 9.42 9.44 12 42 14 12 11 15 17
Selling, General & Admin Expense		 2.06 3.28 4.67 3.35 2.89 7.30 6.35 5.77 4.98 4.89 5.94
Research & Development Expense		 3.49 3.84 4.75 6.09 8.98 35 7.95 6.02 6.41 10 11
Total Other Income / (Expense), net		 -0.81 0.63 0.60 0.56 0.48 2.89 1.74 1.49 -9.14 -5.07 -51
Interest Expense		 - - - - 0.00 - 0.00 - 0.07 - 0.07
Other Income / (Expense), net		 -0.81 0.63 0.60 0.56 0.48 2.89 1.74 1.49 -9.08 -5.01 -51
Income Tax Expense		 0.01 -0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 $0.26 ($0.20) ($0.29) ($0.30) ($0.29) ($1.27) ($0.24) ($0.12) ($0.25) ($0.19) ($0.75)
Weighted Average Basic Shares Outstanding		 21.45M 21.59M 24.52M 25.83M 26.15M 26.72M 33.88M 63.38M 70.64M 62.22M 86.89M
Diluted Earnings per Share		 $0.25 ($0.19) ($0.29) ($0.30) ($0.29) ($1.27) ($0.24) ($0.12) ($0.25) ($0.19) ($0.75)
Weighted Average Diluted Shares Outstanding		 22.41M 21.59M 24.52M 25.83M 26.15M 26.72M 33.88M 63.38M 70.64M 62.22M 86.89M
Weighted Average Basic & Diluted Shares Outstanding		 22.64M 24.81M 25.92M 26.20M 31.57M 45.48M 59.66M 59.91M 68.96M 71.15M 81.40M

Annual Cash Flow Statements for Opus Genetics

This table details how cash moves in and out of Opus Genetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.37 1.38 -2.68 -0.15 1.09 15 8.14 18 7.87 -20 15
Net Cash From Operating Activities		 -17 -13 -15 -19 -3.59 -6.80 -19 14 -1.11 -26 -35
Net Cash From Continuing Operating Activities		 -17 -13 -15 -19 -3.59 -6.80 -19 14 -1.11 -26 -35
Net Income / (Loss) Continuing Operations		 -14 -9.31 -25 -14 -6.17 -25 -57 18 -9.99 -58 -50
Consolidated Net Income / (Loss)		 -14 -9.31 -25 -14 -6.17 -25 -57 18 -9.99 -58 -50
Depreciation Expense		 0.03 0.03 0.04 0.05 0.00 0.01 0.00 0.00 0.01 0.01 0.05
Non-Cash Adjustments To Reconcile Net Income		 -2.64 -3.72 9.21 -4.30 1.10 16 37 -1.58 6.94 28 17
Changes in Operating Assets and Liabilities, net		 -0.29 -0.17 0.66 0.11 0.36 1.15 0.18 -2.00 1.93 3.89 -3.19
Net Cash From Investing Activities		 9.55 4.48 -9.37 12 -0.03 0.54 -0.10 0.00 0.00 1.21 0.00
Net Cash From Continuing Investing Activities		 9.55 4.48 -9.37 12 -0.03 0.54 -0.10 0.00 0.00 1.21 0.00
Divestitures		 - - - - 0.00 2.01 - - - - 0.00
Net Cash From Financing Activities		 8.17 10 22 6.77 4.70 21 28 3.79 8.98 4.19 50
Net Cash From Continuing Financing Activities		 8.17 10 22 6.77 4.70 21 28 3.79 8.98 4.19 50
Repurchase of Common Equity		 - - 0.00 -0.10 0.00 -2.28 -1.51 -0.13 -0.28 -0.23 -2.30
Issuance of Debt		 - - - - 4.71 2.20 0.65 - - 0.00 1.00
Issuance of Common Equity		 7.44 10 17 6.87 - 0.00 28 4.43 9.23 4.50 50
Other Financing Activities, net		 0.73 0.00 5.43 - 0.00 21 0.09 0.03 0.03 -0.08 1.02
Cash Interest Paid		 - - - - 0.00 0.00 0.00 0.01 0.00 0.00 0.00
Cash Income Taxes Paid		 - - - - 0.00 0.00 0.00 0.00 0.34 0.00 0.00

Quarterly Cash Flow Statements for Opus Genetics

This table details how cash moves in and out of Opus Genetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 2.37 8.15 -3.34 -5.75 -4.78 -6.31 11 -9.36 -1.61 14 15
Net Cash From Operating Activities		 -3.00 4.55 -5.72 -7.29 -5.13 -7.44 -8.99 -10 -6.16 -9.83 -13
Net Cash From Continuing Operating Activities		 -3.00 4.55 -5.72 -7.29 -5.13 -7.44 -8.99 -10 -6.16 -9.83 -13
Net Income / (Loss) Continuing Operations		 5.56 -4.80 -7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -17 -66
Consolidated Net Income / (Loss)		 5.56 -4.80 -7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -17 -66
Depreciation Expense		 0.00 0.00 0.00 - - 0.01 0.01 0.01 0.01 0.01 0.01
Non-Cash Adjustments To Reconcile Net Income		 3.24 0.49 1.21 1.05 0.26 26 0.02 0.44 10 6.80 53
Changes in Operating Assets and Liabilities, net		 -12 8.85 0.18 -0.58 2.14 2.15 -0.83 -3.31 1.06 -0.12 -0.29
Net Cash From Investing Activities		 - - 0.00 - - 1.21 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - 1.21 0.00 - - - 0.00
Net Cash From Financing Activities		 5.38 3.60 2.38 1.54 0.35 -0.08 20 0.91 4.54 24 28
Net Cash From Continuing Financing Activities		 5.38 3.60 2.38 1.54 0.35 -0.08 20 0.91 4.54 24 28
Repurchase of Common Equity		 -0.11 -0.17 -0.06 -0.02 -0.10 -0.05 -1.41 -0.09 -0.70 -0.10 -0.36
Issuance of Preferred Equity		 - - - - - - 0.00 - - - 25
Issuance of Common Equity		 5.48 3.75 2.48 1.56 0.46 - 22 - 5.22 23 2.25
Other Financing Activities, net		 - 0.03 -0.04 - - -0.04 -0.03 - 0.02 1.03 0.71
Cash Interest Paid		 - - 0.00 - - - 0.00 - - - 0.00
Cash Income Taxes Paid		 0.32 0.03 0.00 - - - 0.00 - - - 0.00

Annual Balance Sheets for Opus Genetics

This table presents Opus Genetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 25 21 28 16 1.78 18 26 49 54 37 50
Total Current Assets		 25 21 28 16 1.76 18 26 49 54 37 50
Cash & Equivalents		 10 12 8.90 8.74 1.54 16 25 43 51 30 45
Accounts Receivable		 - - - - - - 0.00 1.30 0.93 3.56 2.00
Prepaid Expenses		 1.22 0.61 1.30 1.17 0.15 1.27 1.31 1.45 1.10 0.52 1.79
Other Current Assets		 - - - - 0.08 - 0.00 3.55 1.41 2.21 1.17
Plant, Property, & Equipment, net		 0.11 0.09 0.12 0.11 0.02 0.01 0.01 0.01 0.00 0.25 0.20
Total Noncurrent Assets		 0.03 0.03 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 25 21 28 16 1.78 18 26 49 54 37 50
Total Liabilities		 6.03 3.99 12 5.48 9.34 31 3.86 2.75 4.04 11 35
Total Current Liabilities		 5.40 3.46 11 3.15 9.34 3.19 3.86 2.75 4.04 11 7.78
Accounts Payable		 2.66 1.88 3.23 3.15 0.34 1.21 1.58 1.07 2.15 3.15 3.29
Accrued Expenses		 - - - - 0.62 1.97 1.73 1.68 1.82 8.15 4.49
Total Noncurrent Liabilities		 0.63 0.53 0.43 2.33 0.00 28 0.00 0.00 0.00 0.00 27
Long-Term Debt		 - - - - - - - - - 0.00 1.13
Other Noncurrent Operating Liabilities		 0.53 0.45 0.38 2.31 0.00 28 0.00 - - 0.00 26
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - - - - - 0.00 19 0.00
Total Equity & Noncontrolling Interests		 19 17 17 11 -7.56 -13 22 46 50 6.72 15
Total Preferred & Common Equity		 19 17 17 11 -7.56 -13 22 46 50 6.72 15
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 19 17 17 11 -7.56 -13 22 46 50 6.72 15
Common Stock		 125 132 157 165 0.50 19 112 118 131 146 204
Retained Earnings		 -106 -115 -140 -155 -8.06 -33 -89 -71 -81 -139 -189

Quarterly Balance Sheets for Opus Genetics

This table presents Opus Genetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 54 52 45 40 48 39 36 67
Total Current Assets		 54 52 45 40 48 38 36 67
Cash & Equivalents		 42 47 41 37 42 32 31 60
Accounts Receivable		 10 1.92 1.36 1.86 3.08 3.40 2.92 1.73
Prepaid Expenses		 0.48 1.56 1.11 0.43 1.38 1.43 0.82 3.93
Other Current Assets		 1.21 1.19 0.95 1.47 1.68 1.18 1.36 0.98
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.24 0.23 0.21 0.19
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 54 52 45 40 48 39 36 67
Total Liabilities		 3.91 5.79 4.20 6.09 24 21 30 88
Total Current Liabilities		 3.91 5.79 4.20 6.09 24 20 29 9.34
Accounts Payable		 1.89 2.06 0.63 0.84 2.43 1.47 2.40 4.42
Accrued Expenses		 1.93 3.65 3.49 5.17 9.11 6.93 5.37 4.92
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 1.00 1.07 79
Long-Term Debt		 - - - - - 1.00 1.07 1.20
Other Noncurrent Operating Liabilities		 - - - - - - - 77
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - 19 0.00 0.00 25
Total Equity & Noncontrolling Interests		 50 46 41 34 5.07 17 5.97 -46
Total Preferred & Common Equity		 50 46 41 34 5.07 17 5.97 -46
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 50 46 41 34 5.07 17 5.97 -46
Common Stock		 127 135 137 138 152 172 178 208
Retained Earnings		 -77 -89 -96 -104 -147 -155 -172 -254

Annual Metrics And Ratios for Opus Genetics

This table displays calculated financial ratios and metrics derived from Opus Genetics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 180,747,118.00 237,368,785.00 31,725,114.00 37,521,170.00 4,019,141.00 4,483,198.00 17,300,481.00 20,807,015.00 22,637,600.00 31,568,457.00 68,964,208.00
DEI Adjusted Shares Outstanding		 376,556.00 494,518.00 660,940.00 781,691.00 1,004,785.00 1,120,800.00 17,300,481.00 20,807,015.00 22,637,600.00 31,568,457.00 68,964,208.00
DEI Earnings Per Adjusted Shares Outstanding		 -38.20 -18.82 -38.27 -18.38 -6.14 -21.97 -3.28 0.86 -0.44 -1.82 -0.72
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,665.70% -52.20% -42.30% 29.15%
EBITDA Growth		 23.32% 36.07% -172.74% 40.22% 75.57% -462.69% -176.62% 132.13% -154.72% -477.07% 14.10%
EBIT Growth		 22.62% 36.17% -173.78% 41.39% 67.45% -350.53% -164.36% 132.13% -154.77% -476.82% 14.03%
NOPAT Growth		 -37.64% 10.13% -5.74% -18.34% 79.58% -376.22% -13.71% 212.69% -141.28% -487.66% 37.82%
Net Income Growth		 22.34% 35.30% -171.77% 43.20% 57.07% -299.09% -130.27% 131.55% -155.83% -476.13% 13.80%
EPS Growth		 22.34% 35.30% 100.00% 43.20% 57.07% -143.32% 27.65% 122.77% -152.87% -367.39% 62.79%
Operating Cash Flow Growth		 -57.16% 23.77% -16.58% -22.17% 80.93% -89.17% -184.98% 173.90% -107.77% -2,200.00% -37.84%
Free Cash Flow Firm Growth		 -49.41% 9.43% 58.57% -279.49% 81.91% 439.65% -451.30% 128.24% -126.11% -1,117.61% 91.96%
Invested Capital Growth		 23.76% 30.16% -208.94% 58.63% 17.61% -770.73% 93.33% 278.42% -117.15% -679.67% -501.64%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -66.70% 31.15% -2.99%
EBITDA Q/Q Growth		 -3.05% 18.64% -13.01% 1.94% 64.39% -1,373.67% 14.17% 181.50% -134.27% -111.55% 27.43%
EBIT Q/Q Growth		 -3.06% 18.75% -13.07% 1.83% 53.31% -510.11% 14.17% 181.47% -134.30% -111.56% 27.41%
NOPAT Q/Q Growth		 -2.90% 2.66% -5.98% -0.33% 70.42% -2,044.31% 25.75% 215.60% -125.72% -110.61% 40.78%
Net Income Q/Q Growth		 -4.67% 20.00% -13.80% 3.21% 37.58% -360.83% 17.91% 179.98% -134.73% -111.58% 27.29%
EPS Q/Q Growth		 -4.67% 20.00% 100.00% 3.21% 37.58% -269.23% 6.37% 179.82% -134.33% -100.93% 57.45%
Operating Cash Flow Q/Q Growth		 -9.43% 18.06% -16.74% -5.11% 72.75% -368.38% -7.12% 171.13% -104.81% -88.20% -7.29%
Free Cash Flow Firm Q/Q Growth		 9.30% -17.43% 32.81% -24.72% 73.64% 2,900.99% -101.66% 179.85% -117.22% -278.82% 86.92%
Invested Capital Q/Q Growth		 -24.34% 28.76% -24.49% 32.35% -58.91% -1,162.59% 3.58% 271.04% -107.70% -103.68% -20.33%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,624.28% 45.71% -52.33% -523.31% -348.05%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,854.84% 45.74% -55.45% -564.72% -271.90%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,624.96% 45.70% -52.36% -523.40% -348.42%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,625.30% 44.89% -52.42% -523.40% -349.33%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 98.27% 100.12% 100.00% 100.00%
Interest Burden Percent		 100.76% 102.13% 101.39% 98.26% 129.60% 114.81% 100.00% 99.95% 100.00% 100.00% 100.26%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.73% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,291.82% -501.98% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,291.89% -496.41% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,239.57% 481.20% 0.00% 0.00%
Return on Equity (ROE)		 -63.43% -51.95% -149.55% -105.14% -410.87% 234.18% -1,295.10% 52.26% -20.77% -152.46% -242.41%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 347.63% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -259.11% 48.52% -19.38% -126.71% -113.57%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -259.11% 47.66% -19.40% -126.71% -113.86%
Return on Common Equity (ROCE)		 -63.43% -51.95% -149.55% -105.14% -410.87% 234.18% -1,295.10% 52.26% -20.77% -114.39% -130.77%
Return on Equity Simple (ROE_SIMPLE)		 -76.61% -54.56% -150.84% -136.03% 81.60% 182.82% -255.12% 38.69% -20.01% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -11 -12 -14 -2.94 -14 -16 18 -7.39 -43 -27
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,698.39% 44.95% -38.82% -395.30% -190.33%
Net Nonoperating Expense Percent (NNEP)		 -5.70% 9.97% -55.77% 0.04% -61.04% -173.48% -200.91% -0.07% -5.56% -34.84% -60.77%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -14.82% -646.22% -163.98%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,378.78% 18.24% 62.78% 165.71% 154.85%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,576.06% 36.02% 92.67% 499.01% 217.05%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,954.84% 54.26% 155.45% 664.72% 371.90%
Earnings before Interest and Taxes (EBIT)		 -14 -9.11 -25 -15 -4.76 -21 -57 18 -9.97 -58 -49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -14 -9.15 -25 -15 -3.64 -20 -57 18 -9.97 -58 -49
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.49 1.97 3.82 3.30 0.00 0.00 2.90 1.59 1.37 5.59 9.03
Price to Tangible Book Value (P/TBV)		 3.49 1.97 3.82 3.30 0.00 0.00 2.90 1.59 1.37 5.59 9.03
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 109.56 1.84 3.58 3.42 9.76
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.11 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24.35% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.65 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 68.45 0.77 0.93 2.37 6.67
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.69 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.69 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.72 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.15 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.49 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 -0.75 0.00 0.02 0.00 0.00 0.00 0.07
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07
Financial Leverage		 -1.24 -1.22 -1.39 -1.52 -3.53 0.58 -4.64 -0.98 -0.97 -1.07 -1.82
Leverage Ratio		 1.29 1.28 1.46 1.62 5.94 -0.93 5.00 1.10 1.07 1.20 2.13
Compound Leverage Factor		 1.30 1.31 1.48 1.59 7.69 -1.06 5.00 1.10 1.07 1.20 2.13
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% -299.37% 0.00% 2.36% 0.00% 0.00% 0.00% 6.85%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% -299.37% 0.00% 2.36% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.85%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 73.70% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 399.37% 100.00% 97.64% 100.00% 100.00% 26.30% 93.15%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -1.56 0.00 -0.01 0.00 0.00 0.00 -0.02
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 -1.13 0.00 0.43 0.00 0.00 0.00 0.89
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02
Debt to NOPAT		 0.00 0.00 0.00 0.00 -1.93 0.00 -0.03 0.00 0.00 0.00 -0.04
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 -1.41 0.00 1.52 0.00 0.00 0.00 1.63
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.04
Altman Z-Score		 -0.41 -3.01 -5.79 -11.73 -19.73 -5.47 -0.88 17.14 8.85 -7.31 -4.83
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24.97% 46.05%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.57 6.05 2.54 5.04 0.19 5.55 6.76 17.79 13.35 3.24 6.43
Quick Ratio		 4.34 5.88 2.42 4.67 0.16 5.15 6.42 15.98 12.73 3.00 6.05
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -13 -5.34 -20 -3.67 12 -44 12 -3.23 -39 -3.16
Operating Cash Flow to CapEx		 -27,851.35% -152,632.14% -20,514.12% -48,028.34% -14,372.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -67.44 -41.19 -9.67 0.00 -2.60 3.92 -21,883.25 1,373.51 0.00 0.00 -24.51
Operating Cash Flow to Interest Expense		 -82.19 -42.25 -27.90 0.00 -2.55 -2.14 -9,685.00 1,590.44 0.00 0.00 -273.28
Operating Cash Flow Less CapEx to Interest Expense		 -82.49 -42.27 -28.04 0.00 -2.57 -2.14 -9,685.00 1,590.44 0.00 0.00 -273.28
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.03 1.06 0.37 0.24 0.33
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 17.13 4.90 5.11
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 49.08 4,981.25 0.00 0.00 62.95
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.31 74.53 71.45
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.31 74.53 71.45
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.66 -3.26 -10 -4.16 -3.43 -30 -1.99 3.56 -0.61 -4.76 -29
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 -0.04 50.99 12.93 -4.10 -0.85
Increase / (Decrease) in Invested Capital		 1.45 1.41 -6.81 5.90 0.73 -26 28 5.55 -4.17 -4.15 -24
Enterprise Value (EV)		 42 13 37 20 12 -9.13 40 31 18 26 95
Market Capitalization		 66 34 64 35 7.68 7.27 65 73 68 38 139
Book Value per Share		 $0.10 $0.07 $0.53 $0.28 ($1.88) ($3.00) $1.28 $2.22 $2.20 $0.21 $0.22
Tangible Book Value per Share		 $0.10 $0.07 $0.53 $0.28 ($1.88) ($3.00) $1.28 $2.22 $2.20 $0.21 $0.22
Total Capital		 19 17 17 11 -1.89 -13 23 46 50 26 16
Total Debt		 0.00 0.00 0.00 0.00 5.67 0.00 0.54 0.00 0.00 0.00 1.13
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.13
Net Debt		 -23 -20 -27 -15 4.13 -16 -24 -43 -51 -30 -44
Capital Expenditures (CapEx)		 0.06 0.01 0.08 0.04 0.03 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.18 -2.85 -9.78 -1.98 -3.45 -1.92 -2.00 3.55 -0.61 -5.01 -2.83
Debt-free Net Working Capital (DFNWC)		 19 17 17 13 -1.92 14 23 46 50 25 42
Net Working Capital (NWC)		 19 17 17 13 -7.58 14 22 46 50 25 42
Net Nonoperating Expense (NNE)		 1.60 -2.18 13 -0.01 3.23 11 41 0.02 2.59 14 23
Net Nonoperating Obligations (NNO)		 -23 -20 -27 -15 4.13 -16 -24 -43 -51 -30 -44
Total Depreciation and Amortization (D&A)		 -0.03 -0.03 0.01 -0.29 1.12 0.95 0.00 0.00 0.01 0.01 0.05
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -340.07% 8.91% -3.20% -45.56% -19.92%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,862.48% 116.02% 261.99% 230.30% 297.71%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,771.14% 116.02% 261.99% 230.30% 297.71%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($8.72) ($5.28) ($3.82) $0.90 ($0.46) ($2.15) ($0.80)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 0.00 1.00M 10.93M 14.85M 19.93M 21.59M 26.72M 62.22M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($8.72) ($5.28) ($3.82) $0.87 ($0.46) ($2.15) ($0.80)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 1.00M 10.93M 14.85M 20.60M 21.59M 26.72M 62.22M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($8.72) ($5.28) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 990.04K 4.66M 18.99M 20.95M 24.81M 45.48M 71.15M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -11 -12 -14 -2.94 -14 -16 18 -7.39 -43 -27
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,698.39% 44.95% -38.82% -395.30% -190.33%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,625.30% 45.68% -52.36% -523.40% -349.33%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -67.63 -29.11 -45.15 0.00 -3.38 -6.75 -28,345.50 2,023.56 0.00 0.00 -383.43
NOPAT to Interest Expense		 -60.56 -36.70 -21.98 0.00 -2.08 -4.40 -7,946.75 1,990.07 0.00 0.00 -209.45
EBIT Less CapEx to Interest Expense		 -67.92 -29.13 -45.28 0.00 -3.40 -6.75 -28,345.50 2,023.56 0.00 0.00 -383.43
NOPAT Less CapEx to Interest Expense		 -60.85 -36.72 -22.12 0.00 -2.10 -4.40 -7,946.75 1,990.07 0.00 0.00 -209.45
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.70% 0.00% -9.24% -2.67% 0.73% -2.78% -0.40% -4.64%

Quarterly Metrics And Ratios for Opus Genetics

This table displays calculated financial ratios and metrics derived from Opus Genetics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 21,008,036.00 22,637,600.00 24,813,370.00 25,924,158.00 26,198,444.00 31,568,457.00 45,483,823.00 59,661,197.00 59,908,055.00 68,964,208.00 71,149,045.00
DEI Adjusted Shares Outstanding		 21,008,036.00 22,637,600.00 24,813,370.00 25,924,158.00 26,198,444.00 31,568,457.00 45,483,823.00 59,661,197.00 59,908,055.00 68,964,208.00 71,149,045.00
DEI Earnings Per Adjusted Shares Outstanding		 0.26 -0.21 -0.29 -0.30 -0.29 -1.11 -0.18 -0.12 -0.29 -0.24 -0.92
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -95.76% -2.17% -69.73% -67.60% 154.41% 155.41% 159.17% -20.38% -10.16% -50.64%
EBITDA Growth		 223.09% -113.99% -22.73% -56.55% -234.97% -632.69% -15.13% 4.62% -130.84% 53.17% -700.06%
EBIT Growth		 223.04% -114.00% -22.71% -56.52% -235.00% -632.44% -15.31% 4.44% -131.01% 53.15% -698.95%
NOPAT Growth		 300.53% -111.21% -25.72% -54.54% -188.01% -600.48% -28.81% -6.94% -3.77% 69.88% -44.67%
Net Income Growth		 222.73% -114.13% -22.71% -56.52% -235.34% -632.74% -15.31% 4.44% -131.92% 52.97% -699.79%
EPS Growth		 213.64% -111.18% -3.57% -25.00% -216.00% -568.42% 17.24% 60.00% 13.79% 85.04% -212.50%
Operating Cash Flow Growth		 33.24% -84.20% -56.77% -837.31% -70.83% -263.54% -57.35% -40.83% -20.02% -32.20% -41.51%
Free Cash Flow Firm Growth		 -14.71% -98.71% 75.71% -82.15% 228.09% -6,245.56% 579.71% 194.52% 236.09% 170.48% 428.93%
Invested Capital Growth		 481.00% -117.15% -149.51% 66.10% -129.48% -679.67% -1,511.99% -1,693.83% -918.42% -501.64% -346.72%
Revenue Q/Q Growth		 224.85% -85.83% 1.18% -35.01% 247.75% 11.25% 1.58% -34.05% 6.84% 25.53% -44.19%
EBITDA Q/Q Growth		 212.42% -185.98% -48.23% -9.27% 3.08% -366.72% 76.71% 9.47% -134.58% 5.32% -297.91%
EBIT Q/Q Growth		 212.38% -186.04% -48.13% -9.27% 3.08% -366.85% 76.68% 9.45% -134.31% 5.31% -297.68%
NOPAT Q/Q Growth		 268.86% -159.66% -41.98% -8.04% 3.83% -374.83% 73.89% 10.30% 6.68% -37.81% -25.42%
Net Income Q/Q Growth		 212.09% -186.23% -48.20% -9.27% 3.08% -366.85% 76.68% 9.45% -135.23% 5.33% -296.63%
EPS Q/Q Growth		 204.17% -176.00% -52.63% -3.45% 3.33% -337.93% 81.10% 50.00% -108.33% 24.00% -294.74%
Operating Cash Flow Q/Q Growth		 -403.64% 251.45% -225.68% -27.57% 29.65% -44.99% -20.92% -14.18% 40.04% -59.70% -29.43%
Free Cash Flow Firm Q/Q Growth		 10.00% 110.07% -659.64% -258.97% 163.29% -583.35% 143.68% -29.27% 125.05% 1.37% 227.82%
Invested Capital Q/Q Growth		 445.14% -107.70% -81.80% 29.85% -200.13% -103.68% -275.88% 21.93% -70.39% -20.33% -179.10%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 46.72% -283.50% -415.31% -698.29% -194.62% -816.48% -187.21% -256.97% -564.24% -425.59% -3,034.45%
Operating Margin		 53.51% -321.05% -450.50% -748.92% -207.11% -883.98% -227.21% -309.02% -269.93% -296.33% -665.92%
EBIT Margin		 46.71% -283.68% -415.31% -698.29% -194.62% -816.71% -187.51% -257.46% -564.66% -425.93% -3,035.05%
Profit (Net Income) Margin		 46.59% -283.56% -415.31% -698.29% -194.62% -816.71% -187.51% -257.46% -566.87% -427.50% -3,038.25%
Tax Burden Percent		 99.75% 99.96% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.39% 100.37% 100.11%
Effective Tax Rate		 0.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 1,045.30% -2,906.32% -10,601.37% 0.00% -435.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 1,048.17% -2,904.19% -10,597.40% 0.00% -430.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -949.66% 2,815.20% 10,460.12% 0.00% 401.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 95.64% -91.12% -141.25% -36.01% -33.27% -152.46% -167.55% -200.57% -338.75% -242.41% -7,594.60%
Cash Return on Invested Capital (CROIC)		 236.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 77.73% -104.99% -162.38% -260.17% -34.49% -197.72% -51.19% -95.10% -215.99% -138.83% -632.76%
Return on Assets (ROA)		 77.53% -104.95% -162.38% -260.17% -34.49% -197.72% -51.19% -95.10% -216.83% -139.35% -633.42%
Return on Common Equity (ROCE)		 95.64% -91.12% -141.25% -36.01% -33.27% -114.39% -122.43% -200.57% -338.75% -130.77% 109,935.64%
Return on Equity Simple (ROE_SIMPLE)		 57.18% 0.00% -24.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 6.37 -3.80 -5.40 -5.83 -5.61 -27 -6.95 -6.23 -5.82 -8.02 -10
NOPAT Margin		 53.37% -224.74% -315.35% -524.24% -144.98% -618.79% -159.05% -216.32% -188.95% -207.43% -466.15%
Net Nonoperating Expense Percent (NNEP)		 -2.87% -2.13% -3.97% -4.75% -4.86% -21.07% -2.80% -3.26% -35.06% -22.90% -110.35%
Return On Investment Capital (ROIC_SIMPLE)		 - -7.61% -11.72% -14.35% -16.34% -395.90% -137.01% -33.75% -82.70% -48.66% 22.53%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 17.22% 193.91% 272.94% 301.62% 74.84% 169.62% 145.22% 200.07% 161.77% 126.52% 275.57%
R&D to Revenue		 29.28% 227.14% 277.56% 547.30% 232.27% 814.37% 181.99% 208.95% 208.15% 269.81% 490.36%
Operating Expenses to Revenue		 46.49% 421.05% 550.50% 848.92% 307.11% 983.98% 327.21% 409.02% 369.93% 396.33% 765.92%
Earnings before Interest and Taxes (EBIT)		 5.58 -4.80 -7.11 -7.77 -7.53 -35 -8.19 -7.42 -17 -16 -65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 5.58 -4.79 -7.11 -7.77 -7.53 -35 -8.18 -7.41 -17 -16 -65
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.40 1.37 1.08 0.98 1.00 5.59 8.80 3.22 16.57 9.03 0.00
Price to Tangible Book Value (P/TBV)		 1.40 1.37 1.08 0.98 1.00 5.59 8.80 3.22 16.57 9.03 0.00
Price to Revenue (P/Rev)		 1.23 3.58 2.62 2.41 4.10 3.42 3.27 3.64 6.76 9.76 27.02
Price to Earnings (P/E)		 2.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 40.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.49 0.93 0.14 0.00 0.00 2.37 1.59 1.61 4.72 6.67 24.18
Enterprise Value to EBITDA (EV/EBITDA)		 0.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 1.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 1.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.09
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.18 0.07 -0.06
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.18 0.07 -0.06
Financial Leverage		 -0.91 -0.97 -0.99 -1.04 -0.93 -1.07 -1.27 -1.25 -1.65 -1.82 -35.71
Leverage Ratio		 1.11 1.07 1.11 1.13 1.12 1.20 1.43 1.44 1.90 2.13 40.82
Compound Leverage Factor		 1.11 1.07 1.11 1.13 1.12 1.20 1.43 1.44 1.91 2.14 40.86
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.41% 15.18% 6.85% -6.02%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.41% 15.18% 6.85% -6.02%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 73.70% 78.79% 0.00% 0.00% 0.00% -124.29%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 26.30% 21.21% 94.59% 84.82% 93.15% 230.31%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 -0.02 -0.01
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.54 0.44 0.89 0.55
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 -0.02 -0.01
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 -0.04 -0.04
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.69 0.65 1.63 1.95
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 -0.04 -0.04
Altman Z-Score		 11.33 9.17 3.76 3.54 0.39 -5.31 -2.86 -3.68 -5.66 -2.66 -5.14
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 24.97% 26.93% 0.00% 0.00% 46.05% 1,547.55%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.86 13.35 8.96 10.68 6.63 3.24 1.98 1.90 1.23 6.43 7.13
Quick Ratio		 13.43 12.73 8.48 10.19 6.32 3.00 1.85 1.77 1.16 6.05 6.60
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.63 0.37 -2.05 -7.35 4.65 -22 9.82 6.94 16 16 52
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 229.81 0.00 752.60
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -90.54 0.00 -184.45
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -90.54 0.00 -184.45
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.66 0.37 0.39 0.37 0.18 0.24 0.27 0.37 0.38 0.33 0.21
Accounts Receivable Turnover		 0.00 17.13 7.99 22.03 1.40 4.90 5.46 6.48 6.13 5.11 4.98
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 11,441.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 62.95 56.39
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 21.31 45.68 16.56 261.07 74.53 66.90 56.30 59.53 71.45 73.27
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 21.31 45.68 16.56 261.07 74.53 66.90 56.30 59.53 71.45 73.27
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 7.92 -0.61 -1.11 -0.78 -2.34 -4.76 -18 -14 -24 -29 -80
Invested Capital Turnover		 19.59 12.93 33.62 -10.71 3.00 -4.10 -1.44 -2.09 -1.12 -0.85 -0.25
Increase / (Decrease) in Invested Capital		 10 -4.17 -3.35 1.52 -10 -4.15 -17 -13 -21 -24 -62
Enterprise Value (EV)		 28 18 2.71 -1.75 -2.32 26 22 25 69 95 290
Market Capitalization		 70 68 50 40 34 38 45 56 99 139 324
Book Value per Share		 $2.39 $2.20 $1.86 $1.57 $1.31 $0.21 $0.16 $0.29 $0.10 $0.22 ($0.64)
Tangible Book Value per Share		 $2.39 $2.20 $1.86 $1.57 $1.31 $0.21 $0.16 $0.29 $0.10 $0.22 ($0.64)
Total Capital		 50 50 46 41 34 26 24 18 7.04 16 -20
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.07 1.13 1.20
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.07 1.13 1.20
Net Debt		 -42 -51 -47 -41 -37 -30 -42 -31 -30 -44 -59
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 7.92 -0.61 -1.11 -0.78 -2.34 -5.01 -18 -14 -24 -2.83 -2.70
Debt-free Net Working Capital (DFNWC)		 50 50 46 41 34 25 24 18 6.82 42 57
Net Working Capital (NWC)		 50 50 46 41 34 25 24 18 6.82 42 57
Net Nonoperating Expense (NNE)		 0.81 0.99 1.71 1.94 1.92 8.51 1.24 1.19 12 8.51 55
Net Nonoperating Obligations (NNO)		 -42 -51 -47 -41 -37 -30 -42 -31 -30 -44 -59
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 13.84% -3.20% -5.83% -4.73% -27.86% -45.56% -132.71% -91.97% -163.96% -19.92% -22.52%
Debt-free Net Working Capital to Revenue		 87.89% 261.99% 242.27% 247.04% 409.26% 230.30% 173.45% 118.33% 46.63% 297.71% 477.85%
Net Working Capital to Revenue		 87.89% 261.99% 242.27% 247.04% 409.26% 230.30% 173.45% 118.33% 46.63% 297.71% 477.85%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.26 ($0.20) ($0.29) ($0.30) ($0.29) ($1.27) ($0.24) ($0.12) ($0.25) ($0.19) ($0.75)
Adjusted Weighted Average Basic Shares Outstanding		 21.45M 21.59M 24.52M 25.83M 26.15M 26.72M 33.88M 63.38M 70.64M 62.22M 86.89M
Adjusted Diluted Earnings per Share		 $0.25 ($0.19) ($0.29) ($0.30) ($0.29) ($1.27) ($0.24) ($0.12) ($0.25) ($0.19) ($0.75)
Adjusted Weighted Average Diluted Shares Outstanding		 22.41M 21.59M 24.52M 25.83M 26.15M 26.72M 33.88M 63.38M 70.64M 62.22M 86.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 22.64M 24.81M 25.92M 26.20M 31.57M 45.48M 59.66M 59.91M 68.96M 71.15M 81.40M
Normalized Net Operating Profit after Tax (NOPAT)		 6.37 -3.80 -5.40 -5.83 -5.61 -27 -6.95 -6.23 -5.82 -8.02 -10
Normalized NOPAT Margin		 53.37% -224.74% -315.35% -524.24% -144.98% -618.79% -159.05% -216.32% -188.95% -207.43% -466.15%
Pre Tax Income Margin		 46.71% -283.68% -415.31% -698.29% -194.62% -816.71% -187.51% -257.46% -566.87% -427.50% -3,038.25%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -255.68 0.00 -948.78
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -85.55 0.00 -145.72
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -255.68 0.00 -948.78
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -85.55 0.00 -145.72
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.41% -2.78% -3.00% -2.56% -1.32% -0.40% -2.70% -2.84% -3.30% -4.64% -1.17%

Financials Breakdown Chart

Opus Genetics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Opus Genetics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Opus Genetics' net income appears to be on an upward trend, with a most recent value of -$49.59 million in 2025, rising from -$14.38 million in 2015. The previous period was -$57.53 million in 2024. Check out Opus Genetics' forecast to explore projected trends and price targets.

Opus Genetics' total operating income in 2025 was -$38.60 million, based on the following breakdown:
  • Total Gross Profit: $14.20 million
  • Total Operating Expenses: $52.80 million

Over the last 10 years, Opus Genetics' total revenue changed from $0.00 in 2015 to $14.20 million in 2025, a change of 1,419,600,000.0%.

Opus Genetics' total liabilities were at $34.90 million at the end of 2025, a 208.9% increase from 2024, and a 478.7% increase since 2015.

In the past 10 years, Opus Genetics' cash and equivalents has ranged from $1.54 million in 2019 to $50.50 million in 2023, and is currently $45.09 million as of their latest financial filing in 2025.

Over the last 10 years, Opus Genetics' book value per share changed from 0.10 in 2015 to 0.22 in 2025, a change of 114.2%.


Related Companies

Financial statements for NASDAQ:IRD last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...
Profits Run | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
The tiny chipmaker set to supply Musk 5 billion chips
SpaceX and xAI just completed a $1.25 trillion merger - and Musk may no longer need data centers from Microsof...
Brownstone Research | Sponsoredtc pixel
The market’s crashing? … There’s an app for that
During the Great Financial Crisis, one firm accurately predicted 464 of 465 bank failures before they happened...
Weiss Ratings | Sponsoredtc pixel